Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mucosal protection by cytokines.

Craig C Hofmeister1, Patrick J Stiff

  • 1Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL 60153, USA.

Current Hematology Reports
|October 20, 2005
PubMed
Summary

Oropharyngeal mucositis, a painful side effect of cancer therapy, is now understood to involve complex cytokine interactions. Palifermin is the first approved cytokine therapy to effectively reduce severe oral mucositis in patients with hematologic malignancies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.

The Journal of experimental medicine·2026
Same author

Outcomes of an Alpha-DC-1 Dendritic Cell-Based Vaccine Clinical Trial in Patients with Low-Tumor-Burden High-Risk Ovarian Carcinoma.

Cancers·2026
Same author

QTc Prolongation in Allogeneic Hematopoietic Stem Cell Transplantation: Assessing Cardiac Complications and Survival Outcomes.

Transplantation and cellular therapy·2026
Same author

The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study.

Leukemia·2026
Same author

Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience.

Haematologica·2025

Area of Science:

  • Oncology
  • Cell Biology
  • Pharmacology

Background:

  • Oropharyngeal mucositis (OM) is a debilitating side effect of cancer treatments like chemotherapy and radiation.
  • Historically attributed to direct epithelial damage, OM is now recognized as a complex inflammatory process involving cytokines.
  • Previous cytokine-based therapies for OM yielded inconclusive results or adverse effects.

Purpose of the Study:

  • To review the current understanding of oropharyngeal mucositis pathogenesis.
  • To highlight advancements in therapeutic interventions for OM.
  • To discuss the efficacy of palifermin in managing OM.

Main Methods:

  • Review of existing literature on OM pathogenesis and treatment.
  • Analysis of clinical trial data for cytokine-based therapies.
  • Focus on the mechanism and clinical application of palifermin.

Main Results:

  • Palifermin (recombinant human keratinocyte growth factor) is the first approved cytokine to demonstrate significant reduction in severe OM incidence and duration.
  • Effective in patients with hematologic malignancies undergoing myelotoxic therapy and stem cell support.
  • Other novel agents are currently under investigation in clinical trials.

Conclusions:

  • Significant progress has been made in managing OM after decades of limited options.
  • Palifermin represents a breakthrough in alleviating OM symptoms for cancer patients.
  • Further research into novel agents promises continued improvement in patient care for OM.

Related Experiment Videos